Drug Profile
Research programme: opioid mu receptor antagonists - Merck
Alternative Names: ADL 5510Latest Information Update: 08 Feb 2017
Price :
$50
*
At a glance
- Originator Adolor Corporation
- Class Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyskinesias
Most Recent Events
- 16 Dec 2011 Discontinued - Preclinical for Dyskinesia in USA (PO)
- 12 Dec 2011 Adolor Corporation has been acquired and merged into Cubist Pharmaceuticals
- 05 Nov 2010 Adolor Corporation receives grant from the Michael J. Fox Foundation for opioid mu receptor antagonist development in Levodopa-induced dyskinesia